nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—pancreatic cancer	0.234	0.678	CbGaD
Thalidomide—FGFR2—Sunitinib—pancreatic cancer	0.133	0.349	CbGbCtD
Thalidomide—PTGS2—pancreatic cancer	0.111	0.322	CbGaD
Thalidomide—CYP1A1—Dacarbazine—pancreatic cancer	0.0313	0.0819	CbGbCtD
Thalidomide—CYP1A1—Tamoxifen—pancreatic cancer	0.0249	0.0652	CbGbCtD
Thalidomide—CYP2E1—Dacarbazine—pancreatic cancer	0.0242	0.0633	CbGbCtD
Thalidomide—CYP1A1—Erlotinib—pancreatic cancer	0.0212	0.0554	CbGbCtD
Thalidomide—CYP2E1—Tamoxifen—pancreatic cancer	0.0192	0.0503	CbGbCtD
Thalidomide—CYP3A5—Tamoxifen—pancreatic cancer	0.0149	0.0391	CbGbCtD
Thalidomide—CYP1A2—Dacarbazine—pancreatic cancer	0.014	0.0366	CbGbCtD
Thalidomide—CYP3A5—Erlotinib—pancreatic cancer	0.0127	0.0333	CbGbCtD
Thalidomide—CYP2C19—Tamoxifen—pancreatic cancer	0.0121	0.0315	CbGbCtD
Thalidomide—CYP3A5—Irinotecan—pancreatic cancer	0.0115	0.03	CbGbCtD
Thalidomide—CYP1A2—Tamoxifen—pancreatic cancer	0.0111	0.0291	CbGbCtD
Thalidomide—CYP2C9—Tamoxifen—pancreatic cancer	0.01	0.0262	CbGbCtD
Thalidomide—CYP1A2—Erlotinib—pancreatic cancer	0.00946	0.0248	CbGbCtD
Thalidomide—CYP3A5—Docetaxel—pancreatic cancer	0.00841	0.022	CbGbCtD
Thalidomide—CYP3A5—Sunitinib—pancreatic cancer	0.00837	0.0219	CbGbCtD
Thalidomide—CYP1A2—Fluorouracil—pancreatic cancer	0.0082	0.0215	CbGbCtD
Thalidomide—CYP2C9—Fluorouracil—pancreatic cancer	0.00739	0.0193	CbGbCtD
Thalidomide—Pomalidomide—TNF—pancreatic cancer	0.00138	0.504	CrCbGaD
Thalidomide—Lenalidomide—PTGS2—pancreatic cancer	0.000706	0.257	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—pancreatic cancer	0.000656	0.239	CrCbGaD
Thalidomide—NFKB1—islet of Langerhans—pancreatic cancer	0.000466	0.155	CbGeAlD
Thalidomide—CRBN—islet of Langerhans—pancreatic cancer	0.000391	0.13	CbGeAlD
Thalidomide—NFKB1—digestive system—pancreatic cancer	0.00028	0.0931	CbGeAlD
Thalidomide—CRBN—pancreas—pancreatic cancer	0.000275	0.0914	CbGeAlD
Thalidomide—CRBN—digestive system—pancreatic cancer	0.000235	0.078	CbGeAlD
Thalidomide—FGFR2—digestive system—pancreatic cancer	0.00021	0.0699	CbGeAlD
Thalidomide—PTGS2—gall bladder—pancreatic cancer	0.000162	0.054	CbGeAlD
Thalidomide—CYP3A5—islet of Langerhans—pancreatic cancer	0.000124	0.0412	CbGeAlD
Thalidomide—PTGS2—islet of Langerhans—pancreatic cancer	0.000106	0.0354	CbGeAlD
Thalidomide—CYP2C19—digestive system—pancreatic cancer	9.45e-05	0.0314	CbGeAlD
Thalidomide—CYP3A5—pancreas—pancreatic cancer	8.71e-05	0.029	CbGeAlD
Thalidomide—CYP1A2—digestive system—pancreatic cancer	7.72e-05	0.0256	CbGeAlD
Thalidomide—CYP1A1—digestive system—pancreatic cancer	7.61e-05	0.0253	CbGeAlD
Thalidomide—PTGS2—pancreas—pancreatic cancer	7.48e-05	0.0249	CbGeAlD
Thalidomide—CYP3A5—digestive system—pancreatic cancer	7.44e-05	0.0247	CbGeAlD
Thalidomide—CYP2C9—digestive system—pancreatic cancer	7.32e-05	0.0243	CbGeAlD
Thalidomide—CYP2E1—digestive system—pancreatic cancer	6.94e-05	0.0231	CbGeAlD
Thalidomide—PTGS1—digestive system—pancreatic cancer	6.69e-05	0.0222	CbGeAlD
Thalidomide—PTGS2—digestive system—pancreatic cancer	6.39e-05	0.0212	CbGeAlD
Thalidomide—Sweating—Epirubicin—pancreatic cancer	4.05e-05	0.00025	CcSEcCtD
Thalidomide—Pollakiuria—Doxorubicin—pancreatic cancer	4.05e-05	0.00025	CcSEcCtD
Thalidomide—Asthenia—Gemcitabine—pancreatic cancer	4.04e-05	0.000249	CcSEcCtD
Thalidomide—Haematuria—Epirubicin—pancreatic cancer	4.03e-05	0.000248	CcSEcCtD
Thalidomide—Confusional state—Docetaxel—pancreatic cancer	4.03e-05	0.000248	CcSEcCtD
Thalidomide—Photosensitivity reaction—Doxorubicin—pancreatic cancer	4e-05	0.000247	CcSEcCtD
Thalidomide—Oedema—Docetaxel—pancreatic cancer	4e-05	0.000246	CcSEcCtD
Thalidomide—Weight increased—Doxorubicin—pancreatic cancer	3.99e-05	0.000246	CcSEcCtD
Thalidomide—Epistaxis—Epirubicin—pancreatic cancer	3.99e-05	0.000246	CcSEcCtD
Thalidomide—Pruritus—Gemcitabine—pancreatic cancer	3.99e-05	0.000246	CcSEcCtD
Thalidomide—Infection—Docetaxel—pancreatic cancer	3.97e-05	0.000245	CcSEcCtD
Thalidomide—Weight decreased—Doxorubicin—pancreatic cancer	3.97e-05	0.000245	CcSEcCtD
Thalidomide—Sinusitis—Epirubicin—pancreatic cancer	3.97e-05	0.000244	CcSEcCtD
Thalidomide—Hyperglycaemia—Doxorubicin—pancreatic cancer	3.96e-05	0.000244	CcSEcCtD
Thalidomide—Diarrhoea—Irinotecan—pancreatic cancer	3.96e-05	0.000244	CcSEcCtD
Thalidomide—Agranulocytosis—Epirubicin—pancreatic cancer	3.95e-05	0.000243	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—pancreatic cancer	3.93e-05	0.000242	CcSEcCtD
Thalidomide—Shock—Docetaxel—pancreatic cancer	3.93e-05	0.000242	CcSEcCtD
Thalidomide—Nervous system disorder—Docetaxel—pancreatic cancer	3.92e-05	0.000242	CcSEcCtD
Thalidomide—Pruritus—Fluorouracil—pancreatic cancer	3.92e-05	0.000241	CcSEcCtD
Thalidomide—Thrombocytopenia—Docetaxel—pancreatic cancer	3.91e-05	0.000241	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—pancreatic cancer	3.91e-05	0.000241	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—pancreatic cancer	3.91e-05	0.000241	CcSEcCtD
Thalidomide—Infestation NOS—Doxorubicin—pancreatic cancer	3.91e-05	0.000241	CcSEcCtD
Thalidomide—Tachycardia—Docetaxel—pancreatic cancer	3.9e-05	0.00024	CcSEcCtD
Thalidomide—Skin disorder—Docetaxel—pancreatic cancer	3.88e-05	0.000239	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	3.88e-05	0.000239	CcSEcCtD
Thalidomide—Bradycardia—Epirubicin—pancreatic cancer	3.86e-05	0.000238	CcSEcCtD
Thalidomide—Diarrhoea—Gemcitabine—pancreatic cancer	3.85e-05	0.000238	CcSEcCtD
Thalidomide—Renal failure—Doxorubicin—pancreatic cancer	3.85e-05	0.000237	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—pancreatic cancer	3.83e-05	0.000236	CcSEcCtD
Thalidomide—Dizziness—Irinotecan—pancreatic cancer	3.82e-05	0.000236	CcSEcCtD
Thalidomide—Stomatitis—Doxorubicin—pancreatic cancer	3.81e-05	0.000235	CcSEcCtD
Thalidomide—Anorexia—Docetaxel—pancreatic cancer	3.81e-05	0.000235	CcSEcCtD
Thalidomide—Rhinitis—Epirubicin—pancreatic cancer	3.8e-05	0.000234	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—pancreatic cancer	3.8e-05	0.000234	CcSEcCtD
Thalidomide—Hepatitis—Epirubicin—pancreatic cancer	3.8e-05	0.000234	CcSEcCtD
Thalidomide—Diarrhoea—Fluorouracil—pancreatic cancer	3.79e-05	0.000234	CcSEcCtD
Thalidomide—Hypoaesthesia—Epirubicin—pancreatic cancer	3.78e-05	0.000233	CcSEcCtD
Thalidomide—Pharyngitis—Epirubicin—pancreatic cancer	3.77e-05	0.000232	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—pancreatic cancer	3.75e-05	0.000231	CcSEcCtD
Thalidomide—Urinary tract disorder—Epirubicin—pancreatic cancer	3.75e-05	0.000231	CcSEcCtD
Thalidomide—Oedema peripheral—Epirubicin—pancreatic cancer	3.74e-05	0.00023	CcSEcCtD
Thalidomide—Hypotension—Docetaxel—pancreatic cancer	3.74e-05	0.00023	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—pancreatic cancer	3.73e-05	0.00023	CcSEcCtD
Thalidomide—Urethral disorder—Epirubicin—pancreatic cancer	3.72e-05	0.000229	CcSEcCtD
Thalidomide—Epistaxis—Doxorubicin—pancreatic cancer	3.69e-05	0.000227	CcSEcCtD
Thalidomide—Vomiting—Irinotecan—pancreatic cancer	3.68e-05	0.000227	CcSEcCtD
Thalidomide—Sinusitis—Doxorubicin—pancreatic cancer	3.67e-05	0.000226	CcSEcCtD
Thalidomide—Dizziness—Fluorouracil—pancreatic cancer	3.66e-05	0.000226	CcSEcCtD
Thalidomide—Visual impairment—Epirubicin—pancreatic cancer	3.66e-05	0.000225	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—pancreatic cancer	3.65e-05	0.000225	CcSEcCtD
Thalidomide—Rash—Irinotecan—pancreatic cancer	3.65e-05	0.000225	CcSEcCtD
Thalidomide—Dermatitis—Irinotecan—pancreatic cancer	3.64e-05	0.000225	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	3.64e-05	0.000224	CcSEcCtD
Thalidomide—Headache—Irinotecan—pancreatic cancer	3.62e-05	0.000223	CcSEcCtD
Thalidomide—Insomnia—Docetaxel—pancreatic cancer	3.62e-05	0.000223	CcSEcCtD
Thalidomide—Paraesthesia—Docetaxel—pancreatic cancer	3.59e-05	0.000221	CcSEcCtD
Thalidomide—Erythema multiforme—Epirubicin—pancreatic cancer	3.59e-05	0.000221	CcSEcCtD
Thalidomide—Vomiting—Gemcitabine—pancreatic cancer	3.58e-05	0.000221	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—pancreatic cancer	3.57e-05	0.00022	CcSEcCtD
Thalidomide—Dyspnoea—Docetaxel—pancreatic cancer	3.56e-05	0.00022	CcSEcCtD
Thalidomide—Somnolence—Docetaxel—pancreatic cancer	3.55e-05	0.000219	CcSEcCtD
Thalidomide—Rash—Gemcitabine—pancreatic cancer	3.55e-05	0.000219	CcSEcCtD
Thalidomide—Dermatitis—Gemcitabine—pancreatic cancer	3.55e-05	0.000219	CcSEcCtD
Thalidomide—Eye disorder—Epirubicin—pancreatic cancer	3.55e-05	0.000219	CcSEcCtD
Thalidomide—Tinnitus—Epirubicin—pancreatic cancer	3.54e-05	0.000218	CcSEcCtD
Thalidomide—Headache—Gemcitabine—pancreatic cancer	3.53e-05	0.000217	CcSEcCtD
Thalidomide—Cardiac disorder—Epirubicin—pancreatic cancer	3.52e-05	0.000217	CcSEcCtD
Thalidomide—Vomiting—Fluorouracil—pancreatic cancer	3.52e-05	0.000217	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—pancreatic cancer	3.52e-05	0.000217	CcSEcCtD
Thalidomide—Dyspepsia—Docetaxel—pancreatic cancer	3.52e-05	0.000217	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—pancreatic cancer	3.51e-05	0.000216	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—pancreatic cancer	3.49e-05	0.000215	CcSEcCtD
Thalidomide—Rash—Fluorouracil—pancreatic cancer	3.49e-05	0.000215	CcSEcCtD
Thalidomide—Dermatitis—Fluorouracil—pancreatic cancer	3.49e-05	0.000215	CcSEcCtD
Thalidomide—Pharyngitis—Doxorubicin—pancreatic cancer	3.49e-05	0.000215	CcSEcCtD
Thalidomide—Decreased appetite—Docetaxel—pancreatic cancer	3.47e-05	0.000214	CcSEcCtD
Thalidomide—Headache—Fluorouracil—pancreatic cancer	3.47e-05	0.000214	CcSEcCtD
Thalidomide—Urinary tract disorder—Doxorubicin—pancreatic cancer	3.47e-05	0.000214	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—pancreatic cancer	3.46e-05	0.000213	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	3.45e-05	0.000213	CcSEcCtD
Thalidomide—Fatigue—Docetaxel—pancreatic cancer	3.45e-05	0.000212	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—pancreatic cancer	3.44e-05	0.000212	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—pancreatic cancer	3.44e-05	0.000212	CcSEcCtD
Thalidomide—Nausea—Irinotecan—pancreatic cancer	3.43e-05	0.000212	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—pancreatic cancer	3.43e-05	0.000211	CcSEcCtD
Thalidomide—Mediastinal disorder—Epirubicin—pancreatic cancer	3.42e-05	0.000211	CcSEcCtD
Thalidomide—Pain—Docetaxel—pancreatic cancer	3.42e-05	0.000211	CcSEcCtD
Thalidomide—Constipation—Docetaxel—pancreatic cancer	3.42e-05	0.000211	CcSEcCtD
Thalidomide—Chills—Epirubicin—pancreatic cancer	3.41e-05	0.00021	CcSEcCtD
Thalidomide—Arrhythmia—Epirubicin—pancreatic cancer	3.39e-05	0.000209	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—pancreatic cancer	3.38e-05	0.000209	CcSEcCtD
Thalidomide—Alopecia—Epirubicin—pancreatic cancer	3.35e-05	0.000207	CcSEcCtD
Thalidomide—Nausea—Gemcitabine—pancreatic cancer	3.35e-05	0.000206	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—pancreatic cancer	3.32e-05	0.000205	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—pancreatic cancer	3.32e-05	0.000205	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—pancreatic cancer	3.3e-05	0.000204	CcSEcCtD
Thalidomide—Feeling abnormal—Docetaxel—pancreatic cancer	3.29e-05	0.000203	CcSEcCtD
Thalidomide—Nausea—Fluorouracil—pancreatic cancer	3.29e-05	0.000203	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—pancreatic cancer	3.28e-05	0.000202	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—pancreatic cancer	3.27e-05	0.000202	CcSEcCtD
Thalidomide—Gastrointestinal pain—Docetaxel—pancreatic cancer	3.27e-05	0.000201	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—pancreatic cancer	3.26e-05	0.000201	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—pancreatic cancer	3.26e-05	0.000201	CcSEcCtD
Thalidomide—Tension—Epirubicin—pancreatic cancer	3.24e-05	0.0002	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—pancreatic cancer	3.24e-05	0.000199	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—pancreatic cancer	3.21e-05	0.000198	CcSEcCtD
Thalidomide—Back pain—Epirubicin—pancreatic cancer	3.2e-05	0.000197	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—pancreatic cancer	3.19e-05	0.000196	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—pancreatic cancer	3.18e-05	0.000196	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—pancreatic cancer	3.17e-05	0.000195	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—pancreatic cancer	3.16e-05	0.000195	CcSEcCtD
Thalidomide—Body temperature increased—Docetaxel—pancreatic cancer	3.16e-05	0.000195	CcSEcCtD
Thalidomide—Abdominal pain—Docetaxel—pancreatic cancer	3.16e-05	0.000195	CcSEcCtD
Thalidomide—Chills—Doxorubicin—pancreatic cancer	3.15e-05	0.000194	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—pancreatic cancer	3.14e-05	0.000193	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—pancreatic cancer	3.11e-05	0.000192	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—pancreatic cancer	3.1e-05	0.000191	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—pancreatic cancer	3.08e-05	0.00019	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—pancreatic cancer	3.07e-05	0.000189	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—pancreatic cancer	3.06e-05	0.000188	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—pancreatic cancer	3.05e-05	0.000188	CcSEcCtD
Thalidomide—Agitation—Epirubicin—pancreatic cancer	3.04e-05	0.000187	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—pancreatic cancer	3.01e-05	0.000186	CcSEcCtD
Thalidomide—Tension—Doxorubicin—pancreatic cancer	3e-05	0.000185	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—pancreatic cancer	2.99e-05	0.000184	CcSEcCtD
Thalidomide—Malaise—Epirubicin—pancreatic cancer	2.98e-05	0.000184	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—pancreatic cancer	2.97e-05	0.000183	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—pancreatic cancer	2.97e-05	0.000183	CcSEcCtD
Thalidomide—Syncope—Epirubicin—pancreatic cancer	2.96e-05	0.000183	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—pancreatic cancer	2.96e-05	0.000182	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—pancreatic cancer	2.96e-05	0.000182	CcSEcCtD
Thalidomide—Hypersensitivity—Docetaxel—pancreatic cancer	2.95e-05	0.000182	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—pancreatic cancer	2.94e-05	0.000181	CcSEcCtD
Thalidomide—Palpitations—Epirubicin—pancreatic cancer	2.92e-05	0.00018	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—pancreatic cancer	2.9e-05	0.000179	CcSEcCtD
Thalidomide—Cough—Epirubicin—pancreatic cancer	2.88e-05	0.000178	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—pancreatic cancer	2.88e-05	0.000178	CcSEcCtD
Thalidomide—Asthenia—Docetaxel—pancreatic cancer	2.87e-05	0.000177	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—pancreatic cancer	2.86e-05	0.000176	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—pancreatic cancer	2.85e-05	0.000176	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—pancreatic cancer	2.84e-05	0.000175	CcSEcCtD
Thalidomide—Pruritus—Docetaxel—pancreatic cancer	2.83e-05	0.000174	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—pancreatic cancer	2.83e-05	0.000174	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—pancreatic cancer	2.81e-05	0.000173	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—pancreatic cancer	2.81e-05	0.000173	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—pancreatic cancer	2.81e-05	0.000173	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—pancreatic cancer	2.81e-05	0.000173	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—pancreatic cancer	2.8e-05	0.000173	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	2.79e-05	0.000172	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—pancreatic cancer	2.78e-05	0.000171	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—pancreatic cancer	2.76e-05	0.00017	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—pancreatic cancer	2.75e-05	0.00017	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—pancreatic cancer	2.75e-05	0.000169	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—pancreatic cancer	2.74e-05	0.000169	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—pancreatic cancer	2.74e-05	0.000169	CcSEcCtD
Thalidomide—Diarrhoea—Docetaxel—pancreatic cancer	2.74e-05	0.000169	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—pancreatic cancer	2.72e-05	0.000168	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—pancreatic cancer	2.7e-05	0.000166	CcSEcCtD
Thalidomide—Oedema—Epirubicin—pancreatic cancer	2.7e-05	0.000166	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—pancreatic cancer	2.69e-05	0.000166	CcSEcCtD
Thalidomide—Infection—Epirubicin—pancreatic cancer	2.68e-05	0.000165	CcSEcCtD
Thalidomide—Cough—Doxorubicin—pancreatic cancer	2.67e-05	0.000164	CcSEcCtD
Thalidomide—Shock—Epirubicin—pancreatic cancer	2.65e-05	0.000163	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—pancreatic cancer	2.65e-05	0.000163	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—pancreatic cancer	2.64e-05	0.000163	CcSEcCtD
Thalidomide—Dizziness—Docetaxel—pancreatic cancer	2.64e-05	0.000163	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—pancreatic cancer	2.64e-05	0.000163	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—pancreatic cancer	2.64e-05	0.000163	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—pancreatic cancer	2.63e-05	0.000162	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—pancreatic cancer	2.62e-05	0.000161	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—pancreatic cancer	2.61e-05	0.000161	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—pancreatic cancer	2.6e-05	0.00016	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—pancreatic cancer	2.6e-05	0.00016	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—pancreatic cancer	2.6e-05	0.00016	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—pancreatic cancer	2.59e-05	0.00016	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	2.58e-05	0.000159	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—pancreatic cancer	2.57e-05	0.000158	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—pancreatic cancer	2.57e-05	0.000158	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—pancreatic cancer	2.55e-05	0.000157	CcSEcCtD
Thalidomide—Vomiting—Docetaxel—pancreatic cancer	2.54e-05	0.000157	CcSEcCtD
Thalidomide—Rash—Docetaxel—pancreatic cancer	2.52e-05	0.000155	CcSEcCtD
Thalidomide—Hypotension—Epirubicin—pancreatic cancer	2.52e-05	0.000155	CcSEcCtD
Thalidomide—Dermatitis—Docetaxel—pancreatic cancer	2.52e-05	0.000155	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—pancreatic cancer	2.52e-05	0.000155	CcSEcCtD
Thalidomide—Headache—Docetaxel—pancreatic cancer	2.5e-05	0.000154	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—pancreatic cancer	2.49e-05	0.000154	CcSEcCtD
Thalidomide—Infection—Doxorubicin—pancreatic cancer	2.48e-05	0.000153	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	2.46e-05	0.000151	CcSEcCtD
Thalidomide—Shock—Doxorubicin—pancreatic cancer	2.45e-05	0.000151	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—pancreatic cancer	2.45e-05	0.000151	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—pancreatic cancer	2.44e-05	0.000151	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—pancreatic cancer	2.44e-05	0.00015	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—pancreatic cancer	2.43e-05	0.00015	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—pancreatic cancer	2.42e-05	0.000149	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—pancreatic cancer	2.42e-05	0.000149	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—pancreatic cancer	2.41e-05	0.000149	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—pancreatic cancer	2.4e-05	0.000148	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—pancreatic cancer	2.4e-05	0.000148	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—pancreatic cancer	2.38e-05	0.000147	CcSEcCtD
Thalidomide—Nausea—Docetaxel—pancreatic cancer	2.37e-05	0.000146	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—pancreatic cancer	2.37e-05	0.000146	CcSEcCtD
Thalidomide—Decreased appetite—Epirubicin—pancreatic cancer	2.34e-05	0.000144	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—pancreatic cancer	2.33e-05	0.000144	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	2.33e-05	0.000143	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—pancreatic cancer	2.32e-05	0.000143	CcSEcCtD
Thalidomide—Pain—Epirubicin—pancreatic cancer	2.31e-05	0.000142	CcSEcCtD
Thalidomide—Constipation—Epirubicin—pancreatic cancer	2.31e-05	0.000142	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	2.27e-05	0.00014	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—pancreatic cancer	2.26e-05	0.000139	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—pancreatic cancer	2.24e-05	0.000138	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—pancreatic cancer	2.22e-05	0.000137	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—pancreatic cancer	2.22e-05	0.000137	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—pancreatic cancer	2.22e-05	0.000137	CcSEcCtD
Thalidomide—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.2e-05	0.000136	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—pancreatic cancer	2.2e-05	0.000135	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—pancreatic cancer	2.17e-05	0.000134	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.15e-05	0.000133	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—pancreatic cancer	2.15e-05	0.000133	CcSEcCtD
Thalidomide—Urticaria—Epirubicin—pancreatic cancer	2.14e-05	0.000132	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—pancreatic cancer	2.13e-05	0.000131	CcSEcCtD
Thalidomide—Pain—Doxorubicin—pancreatic cancer	2.13e-05	0.000131	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—pancreatic cancer	2.13e-05	0.000131	CcSEcCtD
Thalidomide—Abdominal pain—Epirubicin—pancreatic cancer	2.13e-05	0.000131	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—pancreatic cancer	2.06e-05	0.000127	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.04e-05	0.000126	CcSEcCtD
Thalidomide—Hypersensitivity—Epirubicin—pancreatic cancer	1.99e-05	0.000122	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—pancreatic cancer	1.98e-05	0.000122	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—pancreatic cancer	1.97e-05	0.000122	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—pancreatic cancer	1.97e-05	0.000122	CcSEcCtD
Thalidomide—Asthenia—Epirubicin—pancreatic cancer	1.93e-05	0.000119	CcSEcCtD
Thalidomide—Pruritus—Epirubicin—pancreatic cancer	1.91e-05	0.000118	CcSEcCtD
Thalidomide—Diarrhoea—Epirubicin—pancreatic cancer	1.84e-05	0.000114	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—pancreatic cancer	1.84e-05	0.000113	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—pancreatic cancer	1.79e-05	0.00011	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—pancreatic cancer	1.78e-05	0.00011	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—pancreatic cancer	1.77e-05	0.000109	CcSEcCtD
Thalidomide—Vomiting—Epirubicin—pancreatic cancer	1.71e-05	0.000106	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—pancreatic cancer	1.71e-05	0.000105	CcSEcCtD
Thalidomide—Rash—Epirubicin—pancreatic cancer	1.7e-05	0.000105	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—pancreatic cancer	1.7e-05	0.000105	CcSEcCtD
Thalidomide—Headache—Epirubicin—pancreatic cancer	1.69e-05	0.000104	CcSEcCtD
Thalidomide—Dizziness—Doxorubicin—pancreatic cancer	1.65e-05	0.000102	CcSEcCtD
Thalidomide—Nausea—Epirubicin—pancreatic cancer	1.6e-05	9.87e-05	CcSEcCtD
Thalidomide—Vomiting—Doxorubicin—pancreatic cancer	1.59e-05	9.78e-05	CcSEcCtD
Thalidomide—Rash—Doxorubicin—pancreatic cancer	1.57e-05	9.69e-05	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—pancreatic cancer	1.57e-05	9.69e-05	CcSEcCtD
Thalidomide—Headache—Doxorubicin—pancreatic cancer	1.56e-05	9.63e-05	CcSEcCtD
Thalidomide—Nausea—Doxorubicin—pancreatic cancer	1.48e-05	9.13e-05	CcSEcCtD
Thalidomide—FGFR2—Disease—PTGS2—pancreatic cancer	6.65e-06	6.39e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—pancreatic cancer	6.62e-06	6.36e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOTCH1—pancreatic cancer	6.61e-06	6.35e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	6.58e-06	6.32e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—pancreatic cancer	6.55e-06	6.29e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CG—pancreatic cancer	6.46e-06	6.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTNNB1—pancreatic cancer	6.44e-06	6.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GLP1R—pancreatic cancer	6.43e-06	6.18e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CD44—pancreatic cancer	6.4e-06	6.15e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—pancreatic cancer	6.4e-06	6.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGF—pancreatic cancer	6.39e-06	6.14e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.38e-06	6.13e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKBIA—pancreatic cancer	6.33e-06	6.08e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DPYD—pancreatic cancer	6.32e-06	6.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—pancreatic cancer	6.29e-06	6.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—pancreatic cancer	6.28e-06	6.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOTCH1—pancreatic cancer	6.27e-06	6.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.26e-06	6.02e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TYMS—pancreatic cancer	6.25e-06	6.01e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMP—pancreatic cancer	6.21e-06	5.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—pancreatic cancer	6.21e-06	5.97e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SRC—pancreatic cancer	6.14e-06	5.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GCG—pancreatic cancer	6.13e-06	5.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CG—pancreatic cancer	6.13e-06	5.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGF—pancreatic cancer	6.06e-06	5.82e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SMAD4—pancreatic cancer	6.03e-06	5.8e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD44—pancreatic cancer	6.02e-06	5.79e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD44—pancreatic cancer	6.01e-06	5.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	6e-06	5.77e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	6e-06	5.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—pancreatic cancer	5.96e-06	5.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CTNNB1—pancreatic cancer	5.95e-06	5.72e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.94e-06	5.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STAT3—pancreatic cancer	5.92e-06	5.69e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—pancreatic cancer	5.9e-06	5.67e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HES1—pancreatic cancer	5.89e-06	5.66e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GLP1R—pancreatic cancer	5.86e-06	5.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SRC—pancreatic cancer	5.82e-06	5.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—pancreatic cancer	5.8e-06	5.57e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GCG—pancreatic cancer	5.77e-06	5.55e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—STK11—pancreatic cancer	5.77e-06	5.54e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DPYD—pancreatic cancer	5.76e-06	5.54e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GCG—pancreatic cancer	5.76e-06	5.54e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	5.73e-06	5.51e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CD—pancreatic cancer	5.68e-06	5.46e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD44—pancreatic cancer	5.68e-06	5.46e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—pancreatic cancer	5.65e-06	5.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—pancreatic cancer	5.61e-06	5.4e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—pancreatic cancer	5.6e-06	5.38e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.56e-06	5.34e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.51e-06	5.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	5.47e-06	5.26e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GCG—pancreatic cancer	5.44e-06	5.23e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—STK11—pancreatic cancer	5.43e-06	5.22e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—STK11—pancreatic cancer	5.42e-06	5.21e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.41e-06	5.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.41e-06	5.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CD—pancreatic cancer	5.39e-06	5.18e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—pancreatic cancer	5.38e-06	5.17e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SRC—pancreatic cancer	5.38e-06	5.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	5.22e-06	5.02e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.22e-06	5.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—pancreatic cancer	5.18e-06	4.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—pancreatic cancer	5.17e-06	4.97e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TERT—pancreatic cancer	5.16e-06	4.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	5.13e-06	4.93e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—STK11—pancreatic cancer	5.12e-06	4.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—pancreatic cancer	5.1e-06	4.9e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—pancreatic cancer	5.08e-06	4.88e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—pancreatic cancer	5.08e-06	4.88e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GLP1R—pancreatic cancer	5.01e-06	4.81e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TYMS—pancreatic cancer	4.96e-06	4.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CB—pancreatic cancer	4.95e-06	4.76e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HIF1A—pancreatic cancer	4.93e-06	4.74e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DPYD—pancreatic cancer	4.93e-06	4.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TSC2—pancreatic cancer	4.92e-06	4.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—pancreatic cancer	4.82e-06	4.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—pancreatic cancer	4.82e-06	4.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—pancreatic cancer	4.82e-06	4.63e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.81e-06	4.62e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—pancreatic cancer	4.8e-06	4.62e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.8e-06	4.62e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.76e-06	4.57e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—pancreatic cancer	4.76e-06	4.57e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—pancreatic cancer	4.71e-06	4.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CB—pancreatic cancer	4.7e-06	4.51e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	4.67e-06	4.49e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TYMS—pancreatic cancer	4.67e-06	4.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—pancreatic cancer	4.67e-06	4.49e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TYMS—pancreatic cancer	4.66e-06	4.48e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD44—pancreatic cancer	4.65e-06	4.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	4.63e-06	4.45e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CG—pancreatic cancer	4.59e-06	4.41e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—pancreatic cancer	4.55e-06	4.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.55e-06	4.37e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—pancreatic cancer	4.51e-06	4.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.51e-06	4.33e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	4.46e-06	4.29e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCG—pancreatic cancer	4.45e-06	4.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—pancreatic cancer	4.45e-06	4.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOTCH1—pancreatic cancer	4.45e-06	4.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—pancreatic cancer	4.43e-06	4.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—pancreatic cancer	4.43e-06	4.26e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—pancreatic cancer	4.43e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TYMS—pancreatic cancer	4.4e-06	4.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—pancreatic cancer	4.39e-06	4.22e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—pancreatic cancer	4.32e-06	4.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—pancreatic cancer	4.32e-06	4.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—pancreatic cancer	4.3e-06	4.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGF—pancreatic cancer	4.3e-06	4.13e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—pancreatic cancer	4.28e-06	4.11e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD44—pancreatic cancer	4.24e-06	4.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—pancreatic cancer	4.21e-06	4.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—STK11—pancreatic cancer	4.19e-06	4.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—pancreatic cancer	4.16e-06	4e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.15e-06	3.99e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.11e-06	3.95e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—pancreatic cancer	4.1e-06	3.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—pancreatic cancer	4.09e-06	3.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—pancreatic cancer	4.08e-06	3.92e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.07e-06	3.91e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCG—pancreatic cancer	4.06e-06	3.9e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—pancreatic cancer	4.06e-06	3.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—pancreatic cancer	4.03e-06	3.88e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CD—pancreatic cancer	4.03e-06	3.88e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SRC—pancreatic cancer	3.97e-06	3.81e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.93e-06	3.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—pancreatic cancer	3.86e-06	3.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—pancreatic cancer	3.83e-06	3.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CD—pancreatic cancer	3.82e-06	3.67e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—STK11—pancreatic cancer	3.82e-06	3.67e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.82e-06	3.67e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—pancreatic cancer	3.82e-06	3.67e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—pancreatic cancer	3.81e-06	3.67e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—pancreatic cancer	3.8e-06	3.65e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—pancreatic cancer	3.79e-06	3.64e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—pancreatic cancer	3.78e-06	3.64e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SRC—pancreatic cancer	3.76e-06	3.62e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—pancreatic cancer	3.67e-06	3.52e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—pancreatic cancer	3.64e-06	3.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—pancreatic cancer	3.63e-06	3.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—pancreatic cancer	3.62e-06	3.48e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD44—pancreatic cancer	3.62e-06	3.48e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—pancreatic cancer	3.62e-06	3.48e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TYMS—pancreatic cancer	3.6e-06	3.46e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.58e-06	3.45e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—pancreatic cancer	3.58e-06	3.44e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—pancreatic cancer	3.55e-06	3.42e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—pancreatic cancer	3.55e-06	3.41e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.54e-06	3.41e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CB—pancreatic cancer	3.51e-06	3.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—pancreatic cancer	3.51e-06	3.38e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.51e-06	3.38e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—pancreatic cancer	3.48e-06	3.35e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—pancreatic cancer	3.48e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCG—pancreatic cancer	3.47e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—pancreatic cancer	3.43e-06	3.29e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	3.42e-06	3.29e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.39e-06	3.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—pancreatic cancer	3.37e-06	3.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—pancreatic cancer	3.36e-06	3.23e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—pancreatic cancer	3.34e-06	3.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CB—pancreatic cancer	3.33e-06	3.2e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—pancreatic cancer	3.31e-06	3.18e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—pancreatic cancer	3.3e-06	3.17e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—pancreatic cancer	3.3e-06	3.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—pancreatic cancer	3.28e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TYMS—pancreatic cancer	3.28e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—STK11—pancreatic cancer	3.26e-06	3.14e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	3.23e-06	3.11e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CD—pancreatic cancer	3.2e-06	3.08e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—pancreatic cancer	3.12e-06	3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—pancreatic cancer	3.12e-06	3e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.06e-06	2.94e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—pancreatic cancer	3.04e-06	2.92e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—pancreatic cancer	3.02e-06	2.9e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CD—pancreatic cancer	3.01e-06	2.9e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	3.01e-06	2.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—pancreatic cancer	2.95e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—pancreatic cancer	2.93e-06	2.82e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—pancreatic cancer	2.92e-06	2.81e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—pancreatic cancer	2.88e-06	2.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—pancreatic cancer	2.86e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	2.84e-06	2.73e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMS—pancreatic cancer	2.81e-06	2.7e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—pancreatic cancer	2.79e-06	2.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CB—pancreatic cancer	2.79e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.77e-06	2.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—pancreatic cancer	2.77e-06	2.66e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—pancreatic cancer	2.67e-06	2.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SRC—pancreatic cancer	2.67e-06	2.57e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—pancreatic cancer	2.65e-06	2.55e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	2.64e-06	2.54e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CB—pancreatic cancer	2.63e-06	2.52e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	2.62e-06	2.52e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—pancreatic cancer	2.6e-06	2.5e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—pancreatic cancer	2.6e-06	2.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—pancreatic cancer	2.57e-06	2.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—pancreatic cancer	2.57e-06	2.47e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—pancreatic cancer	2.55e-06	2.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.53e-06	2.43e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	2.48e-06	2.38e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—pancreatic cancer	2.47e-06	2.37e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—pancreatic cancer	2.45e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	2.41e-06	2.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—pancreatic cancer	2.41e-06	2.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—pancreatic cancer	2.39e-06	2.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—pancreatic cancer	2.39e-06	2.29e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—pancreatic cancer	2.34e-06	2.25e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—pancreatic cancer	2.34e-06	2.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—pancreatic cancer	2.33e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	2.32e-06	2.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—pancreatic cancer	2.28e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—pancreatic cancer	2.27e-06	2.18e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—pancreatic cancer	2.26e-06	2.18e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—pancreatic cancer	2.21e-06	2.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.16e-06	2.08e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—pancreatic cancer	2.14e-06	2.06e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—pancreatic cancer	2.14e-06	2.06e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	2.12e-06	2.04e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	2.06e-06	1.98e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—pancreatic cancer	2.03e-06	1.95e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	2.03e-06	1.95e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—pancreatic cancer	2.01e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.99e-06	1.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—pancreatic cancer	1.88e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.85e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.83e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.81e-06	1.74e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—pancreatic cancer	1.75e-06	1.68e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—pancreatic cancer	1.75e-06	1.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—pancreatic cancer	1.7e-06	1.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—pancreatic cancer	1.66e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—pancreatic cancer	1.6e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	1.6e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—pancreatic cancer	1.6e-06	1.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.58e-06	1.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.56e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	1.51e-06	1.45e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—pancreatic cancer	1.39e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.36e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—pancreatic cancer	1.31e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—pancreatic cancer	1.31e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—pancreatic cancer	1.23e-06	1.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.13e-06	1.08e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—pancreatic cancer	1.01e-06	9.7e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	9.62e-07	9.25e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—pancreatic cancer	9.2e-07	8.84e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—pancreatic cancer	7.86e-07	7.56e-06	CbGpPWpGaD
